Catalyst
Slingshot members are tracking this event:
Ironwood Pharmaceuticals (IRWD) Announces FDA Approval of DUZALLO (lesinurad and allopurinol) for the Treatment of Hyperuricemia in Patients with Uncontrolled Gout
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| IRWD |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Aug 21, 2017
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Duzallo, Lesinurad, Allopurinol, Hyperuricemia, Uncontrolled Gout
